AlloVir, Inc. (NASDAQ:ALVR) Short Interest Update

AlloVir, Inc. (NASDAQ:ALVRGet Free Report) was the target of a large drop in short interest in the month of May. As of May 15th, there was short interest totalling 6,350,000 shares, a drop of 5.5% from the April 30th total of 6,720,000 shares. Based on an average trading volume of 455,800 shares, the short-interest ratio is presently 13.9 days.

Institutional Inflows and Outflows

Institutional investors and hedge funds have recently modified their holdings of the business. Qtron Investments LLC lifted its holdings in AlloVir by 69.2% in the third quarter. Qtron Investments LLC now owns 27,528 shares of the company’s stock worth $59,000 after purchasing an additional 11,263 shares during the period. New York State Common Retirement Fund lifted its stake in shares of AlloVir by 50.6% in the 3rd quarter. New York State Common Retirement Fund now owns 34,388 shares of the company’s stock worth $74,000 after acquiring an additional 11,558 shares during the period. Bank of New York Mellon Corp boosted its holdings in shares of AlloVir by 8.6% in the third quarter. Bank of New York Mellon Corp now owns 167,731 shares of the company’s stock valued at $361,000 after acquiring an additional 13,231 shares in the last quarter. Clear Street Markets LLC acquired a new position in shares of AlloVir during the third quarter valued at approximately $43,000. Finally, Jump Financial LLC bought a new stake in AlloVir during the third quarter worth approximately $78,000. Institutional investors own 66.05% of the company’s stock.

AlloVir Stock Up 1.0 %

AlloVir stock opened at $0.75 on Friday. AlloVir has a 52-week low of $0.58 and a 52-week high of $6.12. The firm has a market capitalization of $87.02 million, a price-to-earnings ratio of -0.45 and a beta of 0.79. The firm has a 50-day moving average price of $0.77 and a two-hundred day moving average price of $0.97.

AlloVir (NASDAQ:ALVRGet Free Report) last issued its quarterly earnings data on Friday, March 15th. The company reported ($0.53) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.43) by ($0.10). Research analysts expect that AlloVir will post -0.26 earnings per share for the current year.

About AlloVir

(Get Free Report)

Allovir, Inc, a clinical-stage cell therapy company, engages in the research and development of allogeneic, off-the-shelf multi-virus specific T cell (VST) therapies to prevent and treat devastating viral-associated diseases. The company's lead product is posoleucel, an allogeneic, off-the-shelf VST therapy, to treat BK virus, cytomegalovirus, adenovirus, Epstein-Barr virus, human herpesvirus 6, and JC virus.

Read More

Receive News & Ratings for AlloVir Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for AlloVir and related companies with's FREE daily email newsletter.